Neuroprotection in Parkinson's disease; a commentary

Neurotoxicity Research

Volumn 4, Issue 2, 2002, Pages 141-145

  Gatto, E M ^b   Riobo N ^a   Carreras, M C ^a   Poderoso, J J ^a   Micheli, F E ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b NONE

Author keywords

Neuroprotection; Parkinson's disease

Indexed keywords

ADENOSINE A2A RECEPTOR ANTAGONIST; AMANTADINE; APOMORPHINE; BRAIN DERIVED NEUROTROPHIC FACTOR; BROMOCRIPTINE; CABERGOLINE; CASPASE INHIBITOR; CATECHOL METHYLTRANSFERASE INHIBITOR; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; ERGOLINE DERIVATIVE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GLUTAMATE RECEPTOR ANTAGONIST; GLUTAMIC ACID; IMMUNOPHILIN; IRON CHELATING AGENT; LEVODOPA; LISURIDE; NERVE GROWTH FACTOR; NITRIC OXIDE; PERGOLIDE; PIRIBEDIL; PRAMIPEXOLE; REMACEMIDE; RILUZOLE; ROPINIROLE; SELEGILINE; TOLCAPONE; UNCLASSIFIED DRUG;

APOPTOSIS; CLINICAL TRIAL; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEGENERATIVE DISEASE; DELUSION; DYSKINESIA; ENERGY; ENVIRONMENTAL FACTOR; HALLUCINATION; HEREDITY; HUMAN; LIVER TOXICITY; LUNG FIBROSIS; MITOCHONDRION; MOTOR DYSFUNCTION; NEUROPROTECTION; NEUROTOXICITY; NOTE; ORTHOSTATIC HYPOTENSION; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RETROPERITONEAL FIBROSIS; SEXUAL DYSFUNCTION; SLEEP DISORDER; SOMNOLENCE;

EID: 0036205586     PISSN: 10298428     EISSN: None     Source Type: Journal    
DOI: 10.1080/10298420290015881     Document Type: Note

References (34)

1. "The molecular mechanism of dopamine-induced apoptosis: Identification and characterization of genes that mediate dopamine toxicity"
2. "Oxidative damage in neurodegenerative diseases"
3. "Effects of riluzole on the electrophysiological activity of pallidal neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkey"
4. "Neuroprotective effects of D3 dopamine receptor agonists"
5. "Amantadine for the treatment of levodopa dyskinesias in Parkinson's disease"
6. "The neurophysiologic basis of abnormal movements in basal ganglia disorders"
7. "Selegiline and mortality in subjects with Parkinson's disease: A longitudinal community study"
8. "Basal ganglia neuronal nitric oxide synthase mRNA expression in Parkinson's disease"
9. "Overexpression of neuronal nitric oxide synthase in Parkinson's disease"
10. "Free radicals"
11. "Pharmacology of selegiline"
12. "Protein nitration in Parkinson's disease"
13. "Influence of time in culture and BDNF pretreatment on survival and function of grafted embryonic rat ventral mesencephalon in the 6-OHDA rat model of Parkinson's disease"
14. "Complications and limitations of drug therapy for Parkinson's disease"
15. "Levodopa Neurotoxicity"
16. "Adenosine A2A receptors modify motor function in MPTP-treated common marmosets"
17. "Parkinson's disease"
18. "MPP+ induced substantia nigra degeneration is attenuated in nNOS knock-out mice"
19. "Pathophysiologic basis of surgery for Parkinson's disease"
20. "Early introduction of dopamine agonist in the long-term treatment of Parkinson's disease"
21. "COMT inhibition in Parkinson's disease"
22. "Current status of selegiline as a neuroprotective agent in Parkinson's Disease"
23. "A randomized, controlled trial of remacemide for motor fluctuations in Parkinson's disease"
24. "Role of the neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity"
25. "Transgenic mice with increased Cu/Zn-superoxide dismutase activity are resistant to N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity"
26. "Workshop IV: drug treatment guidelines for the long-term management of Parkinson's disease"
27. "Glial cell line-derived neurotrophic factor (GDNF) prevents neurodegeneration in models of Parkinson's disease"
28. "Selegiline and mortality in subjects with Parkinson's disease: A longitudinal community study"
29. "Epidemiology of Parkinson's disease"
30. "Modulation of gene expression rather than monoamine oxidase inhibition: (-)-deprenyl-related compounds in controlling neurodegeneration"
31. "Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP subjects not requiring levodopa"
32. "What is it that L-deprenyl (selegiline) might do?"
33. "NMDA receptor-mediated glutamate toxicity of cultured cerebellar, cortical and mesencephalic neurons: Neuroprotective properties of amantadine and memantine"
34. "Iron chelating, antioxidant and cytoprotective properties of dopamine receptor agonists; apomorphine"